MedTrace Logo

Effects of a Food Supplement Composed by BIOintestil ® (Bionocol®) on Microbiota and Inflammatory Profile in Irritable Bowel Syndrome Patients

NCT04340661 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2023-04-18

No results posted yet for this study

Summary

The aim of this double blind placebo-controlled study is to evaluate the effect of BIOintestil on fecal microbiota, inflammatory chemokines and symptoms in patients affected by Irritable Bowel Syndrome (IBS).

Conditions

  • Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

BIOintestil

Ginger ryzoma powder and Palmrose essential oil (Cymbopogon Martinii)

DIETARY_SUPPLEMENT

PLACEBO

Cornstarch

Sponsors & Collaborators

  • Targeting Gut Disease S.R.L.

    lead INDUSTRY

Principal Investigators

  • Fernando Rizzello, MD · A.O.U Policlinico S.Orsola-Malpighi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-05
Primary Completion
2020-09-30
Completion
2021-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04340661 on ClinicalTrials.gov